Satellos Bioscience Inc. (MSCL.TO)
- Previous Close
0.6800 - Open
0.6900 - Bid 0.6500 x --
- Ask 0.6700 x --
- Day's Range
0.6600 - 0.6900 - 52 Week Range
0.4300 - 1.3200 - Volume
90,000 - Avg. Volume
175,991 - Market Cap (intraday)
112.758M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
2.68 - EPS (TTM)
0.2500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.23
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
satellos.comRecent News: MSCL.TO
View MorePerformance Overview: MSCL.TO
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MSCL.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MSCL.TO
View MoreValuation Measures
Market Cap
111.10M
Enterprise Value
64.45M
Trailing P/E
2.68
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.63%
Return on Equity (ttm)
-51.78%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.1M
Diluted EPS (ttm)
0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
69.85M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-16.14M